Impact of three months of rosuvastatin treatment on peripheral endothelial function, inflammatory markers in the blood and the skeletal muscle and on postnatal vasculogenesis in patients with severe chronic heart failure

Trial Profile

Impact of three months of rosuvastatin treatment on peripheral endothelial function, inflammatory markers in the blood and the skeletal muscle and on postnatal vasculogenesis in patients with severe chronic heart failure

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jan 2011

At a glance

  • Drugs Rosuvastatin (Primary)
  • Indications Chronic heart failure
  • Focus Pharmacodynamics
  • Most Recent Events

    • 30 Jul 2007 Status changed from recruiting to completed.
    • 20 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top